Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | RARA | P10276 | 2/20 | 0.41 |
| ▸ | RARB | P10826 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | DNM1L | O00429 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20597986 | 0.90 | MAPK1 (0.42) | SCN10ACYP1A2MAPTCYP2C19RAB9A | |
| SCHEMBL20619910 | 0.89 | MAPT (0.41) | SCN10ACYP1A2MAPTCYP2C19DGAT1 | |
| SCHEMBL20619496 | 0.87 | SCN10A (0.42) | SCN10ACYP1A2MAPTDGAT1RAB9A | |
| SCHEMBL20619600 | 0.87 | SCN10A (0.42) | SCN10ACYP1A2MAPTCYP2C19DGAT1 | |
| SCHEMBL24187965 | 0.86 | MAPT (0.41) | SCN10ACYP1A2MAPTCYP2C19DGAT1 | |
| SCHEMBL17674350 | 0.83 | OGA (0.38) | — | |
| SCHEMBL19149980 | 0.83 | ALDH1A1 (0.49) | MAPTRAB9ATP53KDM4ESMN1; SMN2 | |
| SCHEMBL24187875 | 0.82 | MEN1 (0.36) | SCN10ACYP1A2MAPTDGAT1RAB9A | |
| SCHEMBL20614809 | 0.79 | AVPR2 (0.37) | SCN10A | |
| SCHEMBL20622270 | 0.79 | AVPR2 (0.41) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11534439-B2 | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220016112-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2022-01-20 | — | — | US | disclosed |
| WO-2022010882-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC, (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022010882-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC, (US) | 2022-01-13 | — | — | WO | disclosed |
| US-11179400-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11179400-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10851115-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019199908-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019006291-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| WO-2019006295-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019006291-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019006295-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20190002478-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20190002478-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002478-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | SCN10A 3858/4885CYP1A2 229/4885MAPT 3516/4885 |
| US-11534439-B2 | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors | SIRT5, QDPR, NOX5 | SCN10A 3662/4885CYP1A2 278/4885MAPT 3473/4885 |
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | SCN10A 3763/4885CYP1A2 199/4885MAPT 3526/4885 |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | SCN10A 3763/4885CYP1A2 199/4885MAPT 3526/4885 |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | SCN10A 3858/4885CYP1A2 229/4885MAPT 3516/4885 |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | SCN10A 3858/4885CYP1A2 229/4885MAPT 3516/4885 |
| US-11179400-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | SCN10A 3858/4885CYP1A2 229/4885MAPT 3516/4885 |
| US-10851115-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | SCN10A 3858/4885CYP1A2 229/4885MAPT 3516/4885 |
| US-20220016112-A1 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS | SIRT5, QDPR, NOX5 | SCN10A 3662/4885CYP1A2 278/4885MAPT 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.